Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802183 | 0.81 | KDM4E (0.48) | HPGDKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7799670 | 0.78 | MAPT (0.48) | LMNAHPGDTDP1KMT2AMAPT | |
| SCHEMBL7797675 | 0.76 | KMT2A (0.43) | HPGDKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL7797642 | 0.74 | MAOB (0.39) | LMNATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL7799750 | 0.73 | MAOB (0.42) | KMT2AMAPTMEN1KDM4ENPC1 | |
| SCHEMBL7799225 | 0.72 | LMNA (0.46) | LMNAKMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL7799223 | 0.72 | LMNA (0.46) | LMNAKMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL7799669 | 0.71 | MAPT (0.46) | LMNAHPGDKMT2AMAPTMEN1 | |
| SCHEMBL795101 | 0.70 | MAOB (0.50) | LMNAHPGDKMT2AMAPTALDH1A1 | |
| SCHEMBL7799699 | 0.69 | TSHR (0.44) | KMT2AALDH1A1MAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014694-A1 | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-08-16 | — | — | US | disclosed |
| US-6265428-B1 | VASODILATION | TEXAS BIOTECHNOLOGY CORPORATION | 2001-07-24 | — | — | US | disclosed |
| US-5977117-A | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014694-A1 | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, NPR1 | LMNA 1173/4885HPGD 1273/4885TDP1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.